Ionis Pharmaceuticals price target raised to $67 from $43 at Stifel

Stifel raised the firm’s price target on Ionis Pharmaceuticals (IONS) to $67 from $43 and keeps a Hold rating on the shares. Based on the firm’s view that the total TTR-CM category is likely going to be even bigger than it had anticipated and that eplontersen, per key opinion leaders, is poised to garner meaningful share, the firm is raising its estimates for Ionis and AstraZeneca’s (AZN) eplontersen in TTR-CM, the analyst tells investors.